{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:54:29Z","timestamp":1790178869243,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.chest.2018.01.044","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T13:15:16Z","timestamp":1518009316000},"page":"1125-1133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment"],"prefix":"10.1016","volume":"153","author":[{"given":"Xavier","family":"Pomares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Mont\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Mons\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.chest.2018.01.044_bib1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.01.044_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00019053-200523040-00005","article-title":"Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature","volume":"23","author":"Doll","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.chest.2018.01.044_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.chest.2018.01.044_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2040622314532862","article-title":"Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications","volume":"5","author":"Qureshi","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"issue":"11","key":"10.1016\/j.chest.2018.01.044_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2018.01.044_bib6","unstructured":"From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017. http:\/\/goldcopd.org\/. Accessed October 16, 2017."},{"issue":"3","key":"10.1016\/j.chest.2018.01.044_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MCP.0000000000000154","article-title":"Role of infection in exacerbations of chronic obstructive pulmonary disease","volume":"21","author":"Miravitlles","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.chest.2018.01.044_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2466-14-103","article-title":"Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors","volume":"14","author":"Gallego","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.chest.2018.01.044_bib9","series-title":"Anti-infectives and the Lung (ERS Monograph)","first-page":"185","article-title":"Long-term oral antibiotic treatment: why, what, when and to whom?","author":"Van Braeckel","year":"2017"},{"issue":"11","key":"10.1016\/j.chest.2018.01.044_bib10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2018.01.044_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2018.01.044_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Resp Med"},{"issue":"3","key":"10.1016\/j.chest.2018.01.044_bib13","doi-asserted-by":"crossref","first-page":"e0121257","DOI":"10.1371\/journal.pone.0121257","article-title":"Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.chest.2018.01.044_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMct1115170","article-title":"Antibiotic prevention of acute exacerbations of COPD","volume":"367","author":"Wenzel","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2018.01.044_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12931-016-0425-5","article-title":"Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review","volume":"17","author":"Miravitlles","year":"2016","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.chest.2018.01.044_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.arbres.2017.03.018","article-title":"Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase","volume":"53","author":"Miravitlles","year":"2017","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"10.1016\/j.chest.2018.01.044_bib17","doi-asserted-by":"crossref","first-page":"1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2018.01.044_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/COPD.S23655","article-title":"Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations","volume":"6","author":"Pomares","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.chest.2018.01.044_bib19","first-page":"454","article-title":"Respiratory day hospital: what have we learned?","volume":"136","author":"Pomares","year":"2011","journal-title":"Med Clin (Barc)"},{"issue":"5 suppl 2","key":"10.1016\/j.chest.2018.01.044_bib20","doi-asserted-by":"crossref","first-page":"398S","DOI":"10.1378\/chest.117.5_suppl_2.398S","article-title":"Toward a consensus definition for COPD exacerbations","volume":"117","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2018.01.044_bib21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2018.01.044_bib22","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement","year":"2010"},{"issue":"12","key":"10.1016\/j.chest.2018.01.044_bib23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","article-title":"Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy","volume":"189","author":"Han","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2018.01.044_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.arbres.2008.09.004","article-title":"Causas de muerte en pacientes con EPOC grave. Factores pron\u00f3sticos","volume":"45","author":"Moreno","year":"2009","journal-title":"Arch Bronconeumol"},{"issue":"12","key":"10.1016\/j.chest.2018.01.044_bib25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"suppl 1","key":"10.1016\/j.chest.2018.01.044_bib26","first-page":"2","article-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Diagn\u00f3stico y Tratamiento de Pacientes conEnfermedad Pulmonar Obstructiva Cr\u00f3nica (EPOC)\u2014Gu\u00eda Espa\u00f1ola de la EPOC (GesEPOC). Grupo de Trabajo de GesEPOC","volume":"48","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.chest.2018.01.044_bib27","first-page":"CD009764","article-title":"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)","volume":"11","author":"Herath","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.chest.2018.01.044_bib28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.rmed.2013.04.025","article-title":"Preventing COPD exacerbations: budget impact of a respiratory day hospital and long-term azithromycin therapy","volume":"108","author":"Pomares","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2018.01.044_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/thoraxjnl-2016-208599","article-title":"Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung","volume":"72","author":"Segal","year":"2017","journal-title":"Thorax"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218302459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218302459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:00:17Z","timestamp":1757923217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369218302459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0012369218302459"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2018.01.044","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2018.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}